Technical Analysis for ZNTL - Zentalis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 13.86 -3.21% -0.46
ZNTL closed down 3.21 percent on Monday, March 18, 2024, on 79 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -3.21%
Pocket Pivot Bullish Swing Setup -3.21%
Spinning Top Other -3.21%
Bollinger Band Squeeze Range Contraction -3.21%
Calm After Storm Range Contraction -3.21%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 11 hours ago
Fell Below Previous Day's Low about 15 hours ago
Down 3% about 16 hours ago
Down 2 % about 16 hours ago
Down 1% about 16 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Hormones Her2 Her2/Neu Transcription Factors Estrogen Molecule Therapeutics Antiestrogens Estrogen Receptor Metastatic Breast Cancer Receptor Positive Selective Estrogen Receptor Degraders Intracellular Receptors

Is ZNTL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 31.46
52 Week Low 9.56
Average Volume 850,012
200-Day Moving Average 19.02
50-Day Moving Average 13.57
20-Day Moving Average 14.48
10-Day Moving Average 14.54
Average True Range 1.11
RSI (14) 48.72
ADX 29.56
+DI 23.38
-DI 18.34
Chandelier Exit (Long, 3 ATRs) 14.73
Chandelier Exit (Short, 3 ATRs) 15.42
Upper Bollinger Bands 15.65
Lower Bollinger Band 13.30
Percent B (%b) 0.24
BandWidth 16.19
MACD Line 0.32
MACD Signal Line 0.42
MACD Histogram -0.1061
Fundamentals Value
Market Cap 980.81 Million
Num Shares 70.8 Million
EPS -4.56
Price-to-Earnings (P/E) Ratio -3.04
Price-to-Sales 0.00
Price-to-Book 1.69
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.70
Resistance 3 (R3) 14.74 14.50 14.56
Resistance 2 (R2) 14.50 14.29 14.48 14.51
Resistance 1 (R1) 14.18 14.15 14.06 14.14 14.47
Pivot Point 13.94 13.94 13.88 13.92 13.94
Support 1 (S1) 13.62 13.73 13.50 13.58 13.25
Support 2 (S2) 13.38 13.59 13.36 13.21
Support 3 (S3) 13.06 13.38 13.16
Support 4 (S4) 13.02